Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Net Cash Flow (2021 - 2026)

HeartSciences (HSCS) has disclosed Net Cash Flow for 5 consecutive years, with -$841128.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 192.41% year-over-year to -$841128.0, compared with a TTM value of -$2.1 million through Oct 2025, down 153.16%, and an annual FY2025 reading of -$4.7 million, down 213.56% over the prior year.
  • Net Cash Flow was -$841128.0 for Q4 2025 at HeartSciences, down from $1.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $7.0 million in Q1 2024 and bottomed at -$1.5 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $5287.8, with a median of -$742772.0 recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 709.28% in 2024, while the deepest fall reached 369.1% in 2024.
  • Year by year, Net Cash Flow stood at -$768053.0 in 2021, then plummeted by 55.79% to -$1.2 million in 2022, then surged by 60.26% to -$475510.0 in 2023, then soared by 39.51% to -$287658.0 in 2024, then crashed by 192.41% to -$841128.0 in 2025.
  • Business Quant data shows Net Cash Flow for HSCS at -$841128.0 in Q4 2025, $1.7 million in Q3 2025, and -$1.5 million in Q2 2025.